Post-treatment diffusion MRI-derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics.
MRI scans after prostate cancer radiation may help identify which patients face higher recurrence risk, supporting personalized follow-up.
Diffusion-weighted magnetic resonance imaging (MRI)-derived apparent diffusion coefficient (ADC) has been investigated as a biomarker in prostate cancer, yet its prognostic relevance after definitive radiotherapy remains. While not a standalone predictor, it may support imaging-informed post-treatment risk stratification pending prospective validation.
What the study was
- Study design
- Retrospective study
- Population
- Cancer/disease patients
- Sample size
- 63
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Urologic oncology
Why it surfaced
Matched topic(s): Precision oncology and genomic medicine. Study design: Retrospective study. Score 6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.